Goldman Sachs Maintains Buy on Omada Health, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Neutral 64.0%

Neg 0% Neu 64% Pos 0%

Goldman Sachs analyst David Roman maintains Omada Health (NASDAQ:OMDA) with a Buy and lowers the price target from $26 to $23.